BRAF and neoplasm: TKIs include BRAF inhibitors such as vimofinib, Darafenib, and encofanil, MEK inhibitors comprise trametinib, cobitinib, bemitinib, and Selumetinib, and eventually, the HER2 inhibitor lapatinib (dual EGFR and HER2 targeting), etc. Cetuximab can bind to EGFR on the surface of tumor cells, competitively blocks the EGFR signaling pathway and inhibits the proliferation of tumor cells.